Mortality from systemic lúpus erythematosus in Brazil: analysis of the sociodemographic profile
DOI:
https://doi.org/10.33448/rsd-v11i13.25968Keywords:
Systemic lupus erythematosus; Notification; Epidemiology.Abstract
Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease that presents with symptoms such as fever, weight loss, loss of appetite, weakness and discouragement. Therefore, the study aimed to analyze the profile of SLE in Brazil, from 2010 to 2019. This is a descriptive, epidemiological, exploratory and cross-sectional study, with a quantitative approach, of deaths from SLE reported in the Department of Informatics of the Unified System of Health of Brazil (DATASUS). Data were analyzed in Excel 2010. 10030 cases of death from SLE were reported between 2010 and 2019, with the Southeast region with the highest number of cases (4255 cases) followed by the Northeast (2473 cases). Regarding the profile, there were more deaths in females, with a percentage above 86% for all regions of the country. As for race, in the North, Northeast and Midwest regions, the highest percentage was recorded in the Brown racial group (North - 71.44%; Northeast - 59.28% and Midwest - 50.72%), as for the age group , in the North region, the age between 20 and 29 years was more frequent, corresponding to 25.34% of the cases. In the Northeast and Midwest regions, the age group from 30 to 39 years was more frequent, referring to the percentages of 22.68% and 21.88% respectively. As for education, the patients had, more frequently, from 8 to 11 years of schooling (North - 35.87%; Northeast - 26.85%; Midwest - 30.67%; Southeast 30.3%; and South – 30.12%). The Northeast region presents a smaller quantity of deaths, in relation to the other regions, being predominant in women, of brown color, aged between 31 and 39 years old.
References
Almeida, E. F., Teixeira, J. M. B., & Cardoso, M. Z. (2012). Pesquisa de auto-anticorpos em pacientes com Lúpus Eritematoso Sistêmico: revisão de literatura. Revista Ciências em Saúde, 2 (3).
Appenzeller, S., & Costallat, L. T. L. (2004). Análise de sobrevida global e fatores de risco para óbito em 509 pacientes com lúpus eritematoso sistêmico (LES). Rev Bras Reumatol, 44 (3), 198-205.
Batista, W. L., et.al. (2017). Mortalidade por lúpus eritematoso sistêmico no Brasil de 2005 a 2014. Revista Vita et Sanitas, 11 (1), 3-14.
Brasil. (2013). Ministério da Saúde. Secretaria de Atenção à Saúde. Portaria n.º 100 - Aprova o Protocolo Clínico e Diretrizes Terapêuticas do Lúpus Eritematoso Sistêmico. https://bvsms.saude.gov.br/bvs/publicacoes/protocolos_clinicos_diretrizes_terapeuticas_v3.pdf. Acesso em 09 de julho de 2021.
Borges, C. A., Ribeiro, L. O., Monteiro, M. R. B., da Costa, F. A. M., Lima, Í. C., & Augusto, K. L. (2021). Lúpus Eritematoso Sistêmico Senil: relato de caso e revisão da literatura. Research, Society and Development, 10(11), e580101119837-e580101119837.
Chen, Y., et. al. (2011). Severe Systemic Lupus Erythematosos in Emergency Department: A Retrospective Single-center Study From China. Clin Rheumatol,, 30 (11), 1463-1469.
Costi, L. R., Iwamoto, H. M., Neves, D. C. O., & Caldas, C. A. M. (2017). Mortalidade por Lúpus Eritematoso Sistêmico no Brasil: Avaliação das Causas de Acordo Com o Banco de Dados de Saúde do Governo. Rev Bras Reumatol, 57 (6), 574-582.
Escórcio, I. P. M., de Sousa Oliveira, É. K., Gomes, J. G. F., de Sousa Oliveira, D. K., de Barros Leite, N. F., de Oliveira, G. A. L., & Júnior, L. M. R. (2021). Acompanhamento farmacoterapêutico dos pacientes portadores de Lúpus Eritematoso Sistêmico do município de Piripiri-PI. Research, Society and Development, 10(4), e33110413482-e33110413482.
Fava, A., & Petri, M. (2019). Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun., 96, 1-13. https://pubmed.ncbi.nlm.nih.gov/30448290/. Acesso em 01 abr. 2021.
Fernandes, C. M. J., et. al. (2019). Prevalência dos Casos de Lúpus Eritematoso Sistêmico no Nordeste. Revista Interscientia, 7 (2), 80-97.
Jacinto, M., Silva, E., Riso, N., & Moraes-Fontes, M. F. (2017). Fatores Determinantes de Morbilidade nos Doentes com Lúpus Eritematoso Sistêmico. Acta Med Port, 30 (5), 368-372.
Junior, D. S. T., de Castro, S. B. R., Amorim, A. C., Frisso, A. L., Dias, J. V. L., de Paula Carli, A., & de Souza Alves, C. C. (2021). Study of the environmental and individual factors of autoimmune diseases in the microregion of Águas Formosas–Minas Gerais State, Brazil. Research, Society and Development, 10(4), e29910414138-e29910414138.
Kaul, A., et al. (2016) Systemic lupus erythematosus. Nat Rev Dis Primers., 2, 1-21. https://pubmed.ncbi.nlm.nih.gov/27306639/.
Mezalek, Z. T., & Bono, W. (2014). Challenges for Lupus Management in Emerging Countries. Presse Med, 43, 209–220.
Mocarzel, L. O. C., Gemal, P., Montes, R., Altenburg, R., & Tinoco, C. (2015). Lúpus e Doença Cardiovascular, Int J Cardiovasc Sci. 28 (3): 251-261.
Navarra, S. V., Guzmán, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., Li, E. M., Thomas, M., Kim, H. Y., León, M. G., Tanasescu, C., Nasonov, E., Lan, J. L., Pinela, L., Zhong, Z. J., Freimuth, W., & Petri, M. A. (2011). For the BLISS-52 Study Group. Efficacy and Safety of Belimumab in Patients With Active Sytemic Lupus Erythematosus: a Randomised, Placebo-controlled, Phase 3 trial. Lancet, 377, 721-731.
Petri, M., Orbai, A. M., Alarcón, G. S., Gordon, C., Merrill, J. T., Fortin, P. R., Bruce, I. N., Isenberg, D., Wallace, D. J., Nived, O., Sturfelt, G., Ramsey,G. R., Bae, S. C., Hanly, J. G., Sanchez, G. J., Clarke A., & Aranow, C. (2012). Derivation and Validation of Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum; 64, 2677-2686.
Prado, D. M., et. al. (2017). Perfil dos Pacientes Portadores de Lúpus Eritematoso Sistêmico Atendidos pelo Componente Especializado da Assistência Farmacêutica em Uma Regional de Saúde. Id on Line Rev. Mult. Psic, v. 11, n. 38, 808-823.
Rodrigues, D. D., Nascimento, E. C., Carvalho, L. L., & Silva, R. S. (2017). Diagnóstico Clínico e Laboratorial do Lúpus Eritematoso Sistêmico. Revista de Patologia do Tocantins, 4 (2) 15-20.
Sampaio Júnior, H. C., et. al. (2020). Avaliação dos Sintomas, Complicações, Tratamentos e Efeitos Colaterais Medicamentosos Sobre a Qualidade de Vida de Portadores de Lúpus Eritematoso Sistêmico (LES): Revisão de Literatura. Braz. J. Hea. Rev., 3 (4), 10303-10318.
Santiago, M. P. B., et. al. (2014). Atividade, Gravidade e Prognóstico de Pacientes com Lúpus Eritematoso Sistêmico - Antes, Durante e Após Prima Internação. J Health Biol Sci, 2 (2), 65-73.
Skare, T. L., Dagostini, J. S., Zanardi, P., & Nisihara, R. M. (2016). Infections and Systemic Lupus Eerythematosus. Einstein. 4 (1), 47-51.
Silva, A. M. C., et. al. (2017) Características do Lúpus e Seu Índice de Mortalidade no Estado de Mato Grosso. In: seminário transdisciplinar da saúde, 5, Várzea Grande.
Sociedade Brasileira de Reumatologia. (2019). Lúpus. São Paulo, 22. <https://www.reumatologia.org.br/doencas-reumaticas/lupus-eritematoso-sistemico-les/>
Souza, D. C. C. (2010). Perfil de mortalidade por lúpus eritematoso sistêmico no Estado de São Paulo de 1985 a 2007 (Tese de Doutorado). Universidade Federal de São Paulo, Escola Paulista de Medicina; São Paulo: 107.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Francisco Carlos Carneiro dos Santos; Flávia Cristina Lima de Sousa; José Braz Costa Castro Junior; Sueli de Souza Costa
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
